MetaCap

Oramed Pharmaceuticals (ORMP) vs Atrium Therapeutics (RNA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Oramed Pharmaceuticals is the larger company by market cap ($155.2 million vs $149.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ORMP+4.39%RNA-53.08%
+62%-0%-62%
Feb 27, 20261 yearNov 20, 2026
ORMP+4.39%RNA-53.08%
+52%-3%-58%
Feb 23, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ORMP versus RNA key metrics
MetricORMPRNA
Share price$3.57$6.92
Market cap$155.24M$149.27M
1-day change-3.25%-0.86%
YTD return+25.26%—
1-year return+38.37%—
5-year return-82.34%—
P/E ratio (TTM)1.05—
EPS (TTM)$3.41$-5.22
Dividend yield7.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.00M—
Net income (latest FY)$64.05M—
Gross margin0.65%—
Operating margin-754.40%—
Net margin3202.50%—
52-week high$5.47$16.77
52-week low$2.52$6.36
Distance from 52-week high-34.73%-58.74%
Analyst consensusnonestrong_buy
Avg. price target upside+96.08%+217.92%
Average volume173.38K297.20K
Shares outstanding43.49M21.57M
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Oramed Pharmaceuticals offers a meaningfully higher dividend yield (7.00% vs 0.00%).

About Oramed Pharmaceuticals

ORMP stock →

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.

Health Care · Biotechnology: Pharmaceutical Preparations

About Atrium Therapeutics

RNA stock →

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.

Health Care · Biotechnology: Pharmaceutical Preparations

ORMP vs RNA FAQ

Which is bigger, Oramed Pharmaceuticals or Atrium Therapeutics?

Oramed Pharmaceuticals (ORMP) is larger, with a market capitalization of $155.24M compared with $149.27M for Atrium Therapeutics (RNA).

Which pays a higher dividend, Oramed Pharmaceuticals or Atrium Therapeutics?

Oramed Pharmaceuticals pays a dividend yielding 7.00%, while Atrium Therapeutics does not currently pay a regular dividend.

Are Oramed Pharmaceuticals and Atrium Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons